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Summary Recombinant human erythropoietin (rHuEpo) has recently become available for the treatment of
chronic anaemia, including that associated with cancer. Carcinoma NT in CBA mice causes a progressive
anaemia which can be overcome by daily injections of recombinant human erythropoietin (rHuEpo). This
model was used to study the effect of haematocrit on tumour blood flow, growth rate and radiosensitivity, in
mice with haematocrits ranging from approximately 38% (control) to 65% (20 U/day rHuEpo). Tumours
showed a small but significant slowing in growth rate with higher haematocrit. In vitro studies showed rHuEpo
had no direct effect on the growth of NT cells. Tumour blood flow was measured by two methods in each
mouse ('33Xe clearance and 86Rubidium uptake). Blood flow showed a tendency to decrease with increasing
blood viscosity although this effect was not significant despite the large differences in haematocrit. Although
tumour doubling time was prolonged despite the large differences in haematocrit. Although tumour doubling
time was prolonged with increasing radiation dose, from 0 (sham irradiated) tq 35 Gy, haematocrit was not
found to influence the growth delay. This was attributed to adaptation of the tumour during the relatively
slow change in the haematocrit. rHuEpo is being considered for clinical use in anaemic cancer patients. Our
data suggest that this treatment will correct haematocrit with no effect on tumour radiosensitivity.
Progressive anaemia is a common problem for cancer
patients and is often correlated with an adverse prognosis
(Zucker, 1985; Overgaard, 1989). The aetiology of this
cancer-associated anaemia (CAA) is not fully understood.
However bone marrow production of red cells is not thought
to be defective since erythrocytes are usually normocytic and
normochromic with a low reticulocyte count (Miller et al.,
1992). This suggests that the failure to maintain normal levels
of red cells is due, either to inadequate production of the
erythrocyte growth factor erythropoietin (Epo), or to
interference with its normal mode of action.
Serum Epo levels in CAA have been measured by several
groups (Dainiak et al., 1984; Schreuder et al., 1984; Miller et
al., 1990; Boyd & Lappin, 1991). The reported results show
some discrepancies which may be accounted for in part by
methodological difficulties associated with the biological
assays used in earlier studies (Boyd & Lappin, 1991). In
general when Epo levels in CAA are assessed in relation to
serum haemoglobin, they are usually found to be inapprop-
riately low for the degree of anaemia. The reason for the
failure of cancer patients to produce adequate amounts of
Epo in response to a falling haematocrit is not known.
However Dainiak et al. (1984) have shown that Epo stimula-
tion of red cell function in the bone marrow is normal in
CAA when tested in vitro.
Recombinant human erythropoietin (rHuEpo) has recently
become available and can be administered to compensate for
a deficiency in endogenous Epo production. This approach
has been used to treat the anaemia of chronic renal failure
(Winearls, 1989; Adamson & Eschbach, 1990). Administra-
tion of rHuEpo, by intravenous or subcutaneous routes, gave
a dose-dependent rise in haemoglobin levels within two weeks
in almost all patients. There were no untoward effects of
rHuEpo treatment, apart from a reversible exacerbation of
hypertension in a few patients.
Anaemia in cancer patients is clearly associated with more
advanced disease (Bush et al., 1978) and it has also been
shown to correlate independently with the risk of local
tumour relapse and mortality following radiation treatment
(Dische, 1991). In a major study by Overgaard et al. (1989),
haemoglobin level was shown to have an important influence
on the outcome of radiotherapy treatment to head and neck
tumours, with even small differences in the normal range
having a significant effect. Thus, in clinical practice, patients
receive blood transfusion prior to radiation treatment, when
their haemoglobin is below a pre-determined level, usually
about 10gdl-'. Preliminary clinical studies have already
shown that rHuEpo can correct CAA but this required
higher rHuEpo doses than those needed for the successful
treatment of the anaemia of chronic renal failure (Ludwig et
al., 1990; Taylor et al., 1990; Oster et al., 1990; Miller et al.,
1992). rHuEpo has also been used in cancer patients who
have developed anaemia during platinum-based chemo-
therapy (Miller et al., 1992).
Currently no data are available on the effects of rHuEpo
on tumour radiosensitivity, tumour growth rate or blood
flow. Since rHuEpo has been shown to be effective in revers-
ing CAA in mice (MacManus et al., 1990), this model has
been used to examine these parameters.
Materials and methods
Animals and tumour system
Male CBA mice, 10-14 weeks old, were used in all
experiments. The NT carcinoma, syngeneic to the CBA
strain, was implanted intradermally on the rear dorsum as a
suspension of 2 x 105 cells in 0.05 ml of saline, under
metophane anaesthesia. Tumour size was determined from
the geometric mean of three orthogonal diameters (GMD)
measured with vernier calipers. The tumours took approx-
imately 24 days to reach a GMD of about 7 mm, at which
time the measurements of cardiac output distribution and
tumour blood flow were carried out.
rHuEpo administration
Albumin-free rHuEpo was kindly supplied by Mr P. Mat-
tock, Celltech Ltd., Slough, UK. Aliquots of rHuEpo,
sufficient for 1 day's treatment, were taken from concentrated
stock, placed in polyethylene glycol (PEG) coated tubes, and
returned to storage at - 70°C. Each treatment day one ali-
quot of rHuEpo was thawed and diluted in PEG coated
tubes with normal saline so that the required dose
(0.3125-20 U/mouse/day, i.e. 9.3-600 U/kg/day) could be
delivered in a constant volume of 0.2 ml saline. This was
administered intraperitoneally 5 times weekly.
Correspondence: S.R. McKeown.
Received 13 October 1992; and in revised form 4 June 1993.
Br. J. Cancer (1993), 68, 720-726 '." Macmillan Press Ltd., 1993ERYTHROPOIETIN AND TUMOUR RADIOSENSITIVITY 721
Measurement ofhaematocrit
The haematocrits of all mice were measured on the day of
tumour implant and weekly for the duration of the
experiments. After warming the animals under a lamp, sam-
ples were taken by transecting the last few millimetres of the
tail and allowing 5ftl of blood to be drawn into a small
capillary tube. After sealing the tube with putty it was spun
in a haematocrit centrifuge for 5 min and the haematocrit
was read using a micro-haematocrit reader. This method
allowed repeated weekly determinations of haematocrit with-
out causing significant blood loss.
Measurement of tissue perfusion
Changes in the haematocrit are known to alter blood vis-
cosity and possibly organ perfusion. We used two techniques
to investigate this; one measured absolute changes in tumour
blood flow ('33Xenon clearance) and the other measured the
distribution of cardiac output to different tissues (86Rubidium
uptake). In each mouse the '33Xe clearance determination was
immediately followed by the 86Rb uptake measurement.
133Xenon clearance
The method used was broadly the same as that described by
Kallman et al. (1972). The tumour-bearing mice were posi-
tioned unanaesthetised in a lead jig in front of a sodium
iodide scintillation detector so that it could detect only
radioactivity from the tumour. '33Xe dissolved in saline was
injected into the tumour through a 30 gauge needle at three
points to a depth of a few mm (37 MBq ml-', Amersham
International, Little Chalfont, Bucks). The rate of loss of
radioactivity from the tumour was recorded: in almost all
tumours this could be fitted by a single exponential function.
The half-life of this process was calculated and was regarded
as inversely proportional to the tumour perfusion rate.
Absolute blood flow values requiring measurement or parti-
tion coefficients of '33Xe between blood and tumour were not
considered necessary as we were interested only in relative
changes.
It was suspected that confinement of the animal in a lead
jig for a period of up to 30 min (the time required to obtain
an accurate determination of half life in most tumours) could
be stressful and in itself influence tumour blood flow. This
proved to be the case and this problem was avoided as
described in Jig acclimatisation.
86Rubidium uptake
The 86Rb uptake method (Sapirstein, 1958) was used to
measure the relative cardiac output distribution to tumour
and normal tissues. The isotope (0.185 MBq) was obtained
from Amersham International plc, Aylesbury, UK). It was
prepared in normal saline and 0.1 ml was injected into the
prewarmed tail vein of tumour-bearing mice using a vertical
perspex plate with a groove to hold the base of the tail only.
They were killed 1 min later by cervical dislocation and the
tissues of interest quickly excised, weighed and placed in
tubes for counting in a gamma-counter (LKB Wallac 1282
Compugamma, Pharmacia LKB, Milton Keynes). Uptake
was expressed as percentage of total injected activity per
gram of tissue. Animals were excluded from the analysis if
more than 10% of the injected activity remained at the
injection site.
Jig acclimatisation
The i6Rb uptake method was used to assess the influence of
jig confinement on tumour perfusion. Tumour-bearing mice
were divided into three groups. One group was placed in lead
jigs used in the '33Xe clearance studies for 1 h. This was
continued twice daily for 1 week (only once on the two
weekend days) to acclimatise them to the experience. They
were then placed in the jig for half an hour before injecting
86Rb (while still in the jig) for determination of cardiac
output distribution (see above). The second group received
no acclimatisation and were placed in the jig for half an hour
before injection. The third group received only the 86Rb
injection with no confinement in the jigs.
In vitro assay
Using aseptic technique an NT tumour was removed from a
donor mouse, washed in phosphate buffered saline (PBS) and
mechanically disaggregated. Cells were grown in culture
medium comprising Dulbecco's modified Eagle's medium
with 10% fetal calf serum, 10 mM NaHCO3 and antibiotics.
All incubations were carried out at 37°C in a humid atmos-
phere containing 5% CO2 in air. To assess the effect of
rHuEpo, cells were harvested and prepared at a concentra-
tion of I05 cells per ml in culture medium. The cell suspen-
sion was seeded into 96 well micro-titre plates (0.1 ml per
well) and pre-incubated for 18 h. Culture medium (0.1 ml)
containing rHuEpo was added so that the final rHuEpo
concentration ranged from 31.25 to 64,000 mU ml-'. Six rep-
licate wells were used for each concentration and culture
medium only was added to control wells. After a further
incubation for 24 h, 20 LIl of tritiated thymidine solution
(3HTdr, specific activity 5.0 Ci mmol-1) was added to each
well. Three hours later this was removed by inverting the
dish on several layers of tissue paper; a procedure which did
not result in any significant loss of cells from the wells. After
washing twice with PBS, 0.1 ml of a 1:1 solution of trypsin
(5.2%):versene (2%) was added to each well and incubated
for 10 min at 37°C to detach the cells. After neutralisation
with 0.1 ml of culture medium the cells were harvested on to
glass fibre discs and washed several times using a PHD Cell
Harvester. The filter discs retaining the cells were transferred
to scintillation vials and air dried for 3 h. Three ml of
Biofluor (New England Nuclear, Boston, Ma) were added to
each vial and the 3HTdr incorporation measured in a liquid
scintillation counter (Packard).
Radiation experiments
Protocol I In this experiment tumour bearing mice were
treated with rHuEpo as described under rHuEpo administra-
tion. When the GMD reached 6.5 mm rHuEpo was discon-
tinued and the tumours were irradiated with a single fraction
of 250 kV X-Rays (10, 20 or 30 Gy, dose rate 2.6 Gy min-')
Measurement of tumour size continued after irradiation and
the experiment was terminated when tumour GMD exceeded
12 mm. The growth delay following treatment was assessed
by the time taken for the tumour to double its treatment
volume (tumour doubling time, TDT).
Protocol 2 Two separate tumours were implanted in this
experiment: a flank tumour, to augment the degree of
anaemia and a dorsal tumour implanted 9 days later to be
assessed for radiosensitivity. The flank tumour was surgically
removed on the day before irradiation of the back tumour.
rHuEpo treatment was begun 2 days after implantation of
the flank tumour and continued until the day of irradiation
of the dorsal tumour according to the schedule described in
Protocol 1, except that the daily doses of rHuEpo used were
0, 5 U and 10 U. The GMD of the tumour on the dorsum
was measured three times weekly as in Protocol 1. The
radiation was given as in Protocol 1 but with doses of 0
(sham irradiated), 20, 27.5 and 35 Gy, at a dose rate
2.6 Gymin-'.
Results
Jig acclimatisation
Familiarity with the lead restraining jigs had a highly
significant effect on the distribution of the cardiac output to
the NT tumour (Figure 1). A single confinement in the jig for
30 min prior to 86RbCl injection significantly (P<0.05)722 B. JOINER et al.
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Figure 1 The effect of confinement within a jig on the fractional
distribution of the cardiac output to the NT carcinoma (number
of mice in each group in parentheses). The results for 'jig-trained'
mice is not significantly different from control 'not-jigged' mice
(P = 0.25). 'First time jigged' mice had significantly different
results from controls (P<0.02).
reduced tracer uptake in the tumour by about 30% com-
pared with the group that had never been placed in the jig.
Acclimatisation for 7 days eliminated this difference so that
the uptake of 86Rb was not significantly different from that in
animals tested without any exposure to the jig. Thus, all
subsequent measurements of '33Xe clearance in tumours were
made in animals which had undergone the jig-training proce-
dure.
Effect ofrHuEpo on haematocrit
The effect of various doses of rHuEpo on haematocrit was
followed during growth of the NT carcinoma in a series of
experiments. In animals receiving saline only, there was a
progressive decline in haematocrit with tumour growth
(representative results are shown in Figure 2a and b). The
starting haematocrits in the experiments shown were slightly,
though not significantly different at 52.5% and 48%. In
several other experiments initial haematocrits fell within this
range and were consistent in each experiment. There was no
obvious reason for these differences except that they were
conducted over a 2 year period.
The daily administration of 5 U/mouse of rHuEpo in effect
prevented the decline in haematocrit with tumour growth. A
rHuEpo dose of 20 U/mouse caused a significant rise in the
haematocrit. In one experiment (Figure 2a) rHuEpo injec-
tions were stopped at 28 days allowing haematocrits to fall.
This decline was a relatively rapid process. In all groups,
except those receiving 20 U/day, haematocrits had fallen
within 2 weeks to the same level as the control animals,
which had never received rHuEpo. When rHuEpo was con-
tinued to the end of the measurement period (Figure 2b),
haematocrit levels remained high although the dose of 5 U/
day was not sufficient to prevent anaemia developing with
larger tumour size (GMD 12-14 mm). Haematocrit changes
were also measured in other experiments and similar trends
were observed.
Tumourperfusion
For this investigation tumour perfusion was determined in
each jig-acclimatised mouse, by two different procedures, 1
day after the last rHuEpo treatment.
(1) Washout of '33Xe was used to determine absolute
blood flow in control mice and mice treated daily with saline,
5 U or 20 U or rHuEpo (Table I) until the tumour reached a
GMD of 7.0-8.0 mm. While there was a clear trend towards
increased clearance time with increasing rHuEpo dose the
effect did not reach statistical significance (Mann-Whitney U
test, P=0.13).
(2) Immediately following the '33Xe washout procedure,
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Figure 2 Two separate experiments (a & b) showing the effect of
various daily doses of rHuEpo on haematocrit levels in the
tumour-bearing mouse. Tumours were implanted i.d. on day '0'.
rHuEpo administration began on day '2' and continued for 27
days (a) or 31 days (b), on week days only as denoted by solid
bars. Data points show means ± s.e. for at least 10 animals in
each treatment group.
Table I The effect of rHuEpo on the rate of '33Xenon clearance from
mouse tumours
rHuEpo Dose Number
(units/dayl of 1/Rate of'33Xenon
mouse) mice clearance (min1')a
Control 12 0.091 0.011
5 9 0.077 0.013
(P= 0.41)
20 11 0.066±0.013
(P=0.12)
aResults are expressed as mean ± standard error.
the relative distribution of the cardiac output to liver, kidney,
thigh muscle, gut and tumour was measured using 86Rb
uptake (Figure 3). In tumour there was a trend towards
decreased uptake with increasing rHuEpo dose although this
change was not statistically significant at either dose (20 U/
day vs control, P = 0.1). For the liver and gut there was a
statistically significant reduction in uptake to approximately
70% of the control value after a dose of 20 U/mouse/day
(P<0.001 and P<0.01 respectively). In muscle and kidney
there was no significant change in uptake.
In vivo tumour growth
The administration of rHuEpo from 2 days after transplant
produced small but statistically significant changes in the
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Figure 3 The relationship between cardiac output distribution to i.d. NT carcinomas and to four normal tissues as measured by
the 86Rubidium uptake technique. Mice were treated with either saline, 5 U or 20 U/day of rHuEpo. Error bars show mean ± s.e.
for at least nine mice in each group. Hatched area shows mean ± s.e. for control animals given saline only.
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Table II Mean haematocrits of mice treated with radiation in
protocols I and 2
Treatment Treatment
rHuEpo Dose haematocritr haematocrita
(units/dayl for for
mouse) Protocol I Protocol 2
Control 43.2 ± 0.6 37.7 ± 1.2
(63)
5 51.3±1.1 40.9±1.2
10 46.6± 1.1
20 65.5 ±4.8
aResults are expressed as mean ± standard error.
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Figure 4 The effect of rHuEpo administration on carcinoma NT
size in mice treated daily with saline, 5 U or 20 U of rHuEpo.
Error bars show GMD ± s.e., P = 0.03 for control vs 20 U/day
group.
growth rate of the tumour. Figure 4 shows the GMD as a
function of time after transplant. There was a dose depen-
dent difference in tumour size over the entire experiment
when mice receiving 20 U/day were compared with control
(P = 0.03).
In vitro tumour growth
When cells were incubated with control medium the uptake
of 'HTdR resulted in a count of 37,494 ± 1,978 d.p.m. (mean
from a representative experiment). The mean result for each
of the rHuEpo concentrations tested (31.25 to 64,000 mU
ml-') was not significantly different from this control value,
with less than a 5% variation in the means. These data were
confirmed in three separate experiments.
Tumour radiosensitivity
The two protocols used for the definitive experiments were
designed to test a range of radiation doses on mice with
haematocrits varying from anaemic to frankly polycythaemic
(Table II). Figure 5a shows the effect of a range of haemato-
crits from 43.2 ± 0.6 to 65.5 ± 4.8 on the radiosensitivity of
NT tumours using Protocol 1. There was no significant
difference in radiation induced growth delay between the
groups receiving saline and those receiving either dose of
rHuEpo (P> 0.25). Protocol 2 used a larger tumour burden,
lower rHuEpo doses (37.7 ± 1.2 to 46.6 ± 1.1) and a wider
range of radiation doses, but again no significant difference
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Figure 5 Tumour doubling time (TDT) after single dose irradia-
tion in groups of mice with varying haematocrit produced by
daily injection of recombinant human erythropoietin at different
doses. (a) Protocol 1 (b) Protocol 2 (see Materials and methods
for details).
(P>0.25) was observed in growth delay with varying
haematocrit (Figure Sb).
Discussion
Haematocrit changes I
The effects of rHuEpo administration in these experiments
are broadly similar to those of MacManus et al. (1990). We
also found that haematocrit declined with increasing tumour
burden despite continuing treatment with rHuEpo. This
implies that the tumour exerts an influence which is capable
of inhibiting and overwhelming the action of exogenously
administered rHuEpo. This occurred even at rHuEpo doses
capable of producing marked polycythaemia in non tumour-
bearing animals. We have demonstrated in vitro that condi-
tioned medium from NT cells can inhibit the biological
action of Epo in the mouse spleen cell assay (unpublished
data). This suggests that the NT tumour produces a factor
which interferes with the stimulation of red cell production
by Epo. It has also been shown that Epo levels are not
elevated in anaemic mice bearing the NT tumour (Mac-
Manus et al., 1990) suggesting that anaemia may be induced
by more than one mechanism.
It has been clearly demonstrated that rHuEpo is effective
in correcting CAA in man (Miller et al., 1992). In Figure 6 a
comparison has been made of the percentage changes in
haemoglobin levels as a function of time after various
rHuEpo doses in mouse and man (data from the current
study, Figure 2a, and from Miller et al., 1992). Changes have
been determined relative to pretreatment levels for the human
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Figure 6 The % change in haemoglobin level in mouse and man
as a function of time after various doses (U/kg/day). Human data
were derived from Miller et al., 1992.
data and relative to saline treated controls in mice. Since the
anaemia of cancer is usually normochromic (Miller et al.,
1992) it is probably valid to compare changes in haemo-
globin and haematocrit values. In the mouse a rHuEpo dose
of 38 U/kg/day (1.25 U/day in mice of average weight 33 g)
had a similar effect to 25 or 50 U/kg/day in man. A rHuEpo
dose of 150 U/kg/day (5 U/day) in the mouse was about as
effective as 200 U/kg/day in man. It is interesting to note that
the rate of increase in haemoglobin for both mouse and man
is almost identical during rHuEpo treatment (about 6% per
week for a dose of 100-200 U/kg/day). Obviously these com-
parisons can only be approximate, but it suggests that the
mouse is an acceptable model for studying the effects of
rHuEpo on CAA.
In cancer patients anaemia presents at a stage when the
disease would have been present for some time and the
tumour burden is substantial. rHuEpo treatment is therefore
initiated in humans at a late stage in the disease. This differs
from the present study since rHuEpo treatment was given
from 2 days after tumour implant, at a time when no mac-
roscopic tumour was present and the mice were not anaemic.
The early initiation of rHuEpo treatment in this mouse
model has been shown to be required if anaemia is to be
prevented (MacManus et al., 1990). This may well be due to
the rapid growth of the murine tumour. The significant
influence of tumour burden on the biological action of Epo
was confirmed in mice receiving low doses of rHuEpo
(<5 U/day). In these mice anaemia became apparent as the
tumour burden increases, despite the rHuEpo treatment
(Figure 2).
Jig acclimatisation
Our investigations were designed to allow direct comparison
of tumour perfusion by two different techniques. The first
technique employed was '33Xe washout. This involved
restraining the mouse in a lead jig for up to 40 min. Previous
reports have suggested that this restraint may have a
marked effect on tumour perfusion (Zanelli & Lucas, 1976;
Tozer, 1987). Our results confirmed that the stress associated
with restraint significantly decreased tumour perfusion as
measured by 86Rb uptake (Figure 1). We have demonstrated
that jig acclimatisation for 1 week prior to the experiment
eliminated the change in blood flow. Thus our results support
the contention that stress has a significant influence on
tumour blood flow but that this can be avoided if the mice
have been conditioned to the stress.
Tumour growth rate
The rate of tumour growth will depend on the delivery of
nutrients, particularly oxygen, to proliferating cells. We have
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shown (Figure 4) that there is a small but significant reduc-
tion in tumour growth rate after rHuEpo administration.
There are two possible explanations for this effect: either
rHuEpo may have a direct effect on tumour cell division or it
may act indirectly by alteration of nutrient delivery, partic-
ularly oxygen. Our results show that the growth of tumour
cells in vitro is not significantly altered over a wide range of
concentrations of rHuEpo, including those several times
greater than that likely to be achieved in vivo. Whilst this
does not exclude a direct effect on tumour cells in vivo it
seems unlikely that this mechanism is important.
Thus we conclude that the slowing of tumour growth
probably results from an impairment of oxygen delivery. Is
this consistent with what we know of the relation between
haematocrit and oxygen dependent processes? It has pre-
viously been shown that the radiosensitivity of several mouse
tumours is greatest at haematocrits close to the normal level.
A deviation in either direction results in a tumour with a
higher radiobiological hypoxic fraction (Hirst et al., 1984 &
1985). In those studies the changes in tissue oxygenation were
induced by acute changes in haematocrit, whereas chronic
alterations in haematocrit have been consistently found not
to affect the radiobiological hypoxic fraction (Hirst & Wood,
1987; Koong & Hirst, 1991). There is evidence however that
severe chronic anaemia reduces the growth rate of murine
tumours (Koong & Hirst, 1991), supporting the hypothesis
that haematocrit may have some influence on tumour
growth. Since we have demonstrated that polycythaemia
results in reduced tumour growth and Koong & Hirst (1991)
have shown this for chronic anaemia this suggests that there
may also be an ideal haematocrit range for optimal tumour
growth.
Bloodflow
The flow resistance of blood through a vascular network can
be described by the equation:
FR 8nL FR iR4
where L is vessel length, R, vessel radius and t, blood
viscosity. Therefore, resistance is a linear function of vis-
cosity. However, viscosity is not linearly related to haemato-
crit in vivo, but increases progressively, and more steeply, as
haematocrit rises above about 50% (Sevick & Jain, 1989). At
these high haematocrits the increased haemoglobin content is
not sufficient to compensate for the increased flow resistance
so it has been suggested that a haematocrit optimum for
tissue oxygenation exists for most tissues.
Tumour blood flow was determined to elucidate the possible
influence of tumour perfusion on the growth of tumours
when the haematocrit was increased using rHuEpo. Both the
'33Xe washout and 86Rb uptake methods were carried out in
the same animal to allow a direct comparison between the
different techniques. Broadly similar results for tumour blood
flow were obtained from two methods (Table I and Figure
3). In Figure 7 the paired results from the two assays in
individual mice shows a clear and significant correlation
(r2 = 0.26, P = 0.002). There is some scatter in the data which
may be a consequence of the different parameters measured
by the two techniques: 86Rb uptake gives the average dis-
tribution for the whole tumour whereas '33Xe washout yields
highly focal information, predominantly from the central
part of the tumour.
In our study absolute tumour blood flow (from 133Xe
clearance) in animals treated with 20 U/day fell to 73% of
control while the distribution of the cardiac output (deter-
mined from 86Rb uptake) fell to 79% of control. These
changes are consistent with a small reduction in cardiac
output as a consequence of the increased viscosity that
results from a high haematocrit. However, despite variations
in haematocrit from approximately 38-65%, we were unable
to demonstrate a significant change in tumour blood flow by
either experimental method, although there was a tendency
for tumour blood flow to fall with increasing haematocrit.
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Figure 7 A correlation of paired results obtained by '33Xenon
washout and 86Rubidium extraction techniques carried out in the
same mouse (r2 = 0.26; P = 0.002).
This suggests that there are compensatory mechanisms which
are sufficient to overcome the deleterious effects of the in-
creased viscosity when the change in haematocrit occurs
slowly over several weeks.
Tumour radiosensitivity
Tumour radiosensitivity was assessed in the present study
over a range of radiation doses where hypoxic cells would be
expected to dominate the response. Therefore changes in the
oxygenation status of the tumour due to haematocrit altera-
tion should have been reflected as changes in radiosensitivity.
The data from the two experimental protocols provides in-
formation for groups of mice with haematocrits ranging from
moderately anaemic (37.7%), through to severely poly-
cythaemic (65.5%) on the day of irradiation (Table II). It is
perhaps unexpected that no significant different in radiosen-
sitivity was seen between any of these groups (Figures 5a and
Sb) given the wide range of haematocrits tested.
The effect of changes in haematocrit on radiosensitivity has
been examined previously in several different murine models.
Hirst and Wood (1987) have shown that although an acute
increase in haematocrit caused an immediate increase in
radiation sensitivity, this effect was no longer apparent after
6 h. Earlier studies by Hirst et al. (1984), using different
murine tumours, had found that the time for the radiation
sensitivity to return to normal following an acute change in
haematocrit was around 24 h. These results are consistent
with the view that a variety of mechanisms act to compensate
for loss of oxygen carrying capacity (Hirst & Wood, 1987).
Koong & Hirst (1991) showed only very small changes in
radiosensitivity of KHT tumours in mice made anaemic by
tumour growth (as in the present study) or by iron deficiency.
In general, chronic changes in haematocrit in the mouse have
not led to significant alterations in tumour radiosensitivity,
probably as a result ofphysiological adaptation (Hirst, 1986).
An important exception to this however is the study of Rojas
et al. (1987) in which anaemia was induced by renal irradia-
tion. However the animals in this study were at least 9
months of age, much older than in other studies.
In this paper we have reported some of the consequences
of rHuEpo administration on tumour perfusion, growth and
radiosensitivity. The results show that there is no change in
tumour radiosensitivity despite large changes in haematocrit.
This finding can probably be attributed to the prolonged
time course of the change in haematocrit which permitted
physiological adaptation.
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